Ignite Creation Date:
2025-12-24 @ 8:03 PM
Ignite Modification Date:
2026-01-05 @ 6:22 PM
Study NCT ID:
NCT02069704
Status:
COMPLETED
Last Update Posted:
2019-07-23
First Post:
2014-02-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
Sponsor:
mAbxience Research S.L.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-10-29
Start Date Type:
ACTUAL
Primary Completion Date:
2015-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-06
Completion Date Type:
ACTUAL
First Submit Date:
2014-02-14
First Submit QC Date:
None
Study First Post Date:
2014-02-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-12-03
Results First Submit QC Date:
None
Results First Post Date:
2019-07-23
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-07-19
Last Update Post Date:
2019-07-23
Last Update Post Date Type:
ACTUAL